References
- Steg PG, Goldberg RJ, Gore JM, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002;90:358–63
- EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Eur Heart J 2001;22:554–72
- Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. Eur Heart J 2002;23:1190–201
- OECD Economic Outlook 76 Database. OECD. http://www. oecd.org/document/61/0,2340,en_2825_32066506_2483901_ 1_1_1_1,00.html . 2004. 1–3–2005. [Last accessed 7 Nov 2006]
- In TIME II Investigators. Geographic variation in patient, and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Eur Heart J 2001;22:1702–15
- Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations in practice and outcome. Eur Heart J 2002;23:1177–89
- Penny WJ. Patient delay in calling for help: the weakest link in the chain of survival? Heart 2001;85:121–2
- Fox KA, Goodman SG, Anderson FA, et al. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. Eur Heart J 2003;24:1414–24
- Fox KA, Cokkinos DV, Deckers J, et al. The ENACT Study: a pan-European survey of acute coronary syndromes. Eur Heart J 2000;21:1440–9
- Dickson M, Jacobzone S. Pharmaceutical use and expenditure for cardiovascular disease and stroke: a study of 12 OECD countries. OECD Health Working Paper 2003;1
- Department of Health. Reference Costs 2002. London: Department of Health, 2003
- Agence Technique de l’Information sur l’Hospitalisation. Echelle nationale des coûts relatifs par GHM. France, 2003
- Detournay B, Huet X, Fagnani F, Montalescot G. Economic evaluation of enoxaparin sodium versus heparin in unstable angina: a French sub-study of the ESSENCE trial. Pharmaco-economics 2000;18:83–9
- G-DRG. Verordnung zum Fallpauschalensystem für Krankenhäuser für das Jahr 2004. Fallpauschalenverordnung 2004 – KFPV 2004. 2003;13
- G-DRG Group. G-DRG Version 2004: Fallpauschalenkatalog für Hauptabteilungen bzw. Belegabteilungen. In Klauber J, Robra B-P, Schellschmidt H, eds. Krankenhaus-Report 2003. Stuttgart: Schattauer, 2004
- Consejo General de Colegios Oficiales de Farmaceuticos. Consumer price PVP. Spain, 2003
- Reverte D, Moreno JJ, Ferreira EM. Hipertension Arterial: Actualizacion de su tratamiento. Informacion Terapeutica del Sistema Nacional de Salud, Spain, 1998;22
- Blasco A, Gonzalez A, Lobos JM, Silva L. Tratamiento medico de la angina estable: farmacos antianginosos y prevencion secundaria de la cardiopatia isquemica. Informacion Terapeutica del Sistema Nacional de Salud, Spain, 2003;27
- Danchin N, Macaya C, Tao WY. Economic analysis of the use of contrast media during percutaneous coronary intervention (PCI) in France and Spain. Value in Health 2003;6:659
- British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary 46, 2003. London: Royal Pharmaceutical Society of Great Britain
- Department of Health. Prescription Cost Analysis 2002. London, 2002
- Sanitaria Farmaceutica. Giofil 2003, 2003. Italy. Report
- Assurance Maladie en Ligne. Guide des équivalents thérapeutiques. France, 2003
- Schwabe U, Paffrath D. Arzneiverordnungs Report 2003. Berlin: Springer, 2003
- Netten A, Curtis L. Unit costs of health and social care 2002. University of Kent, UK: Personal Social Services Research Unit
- Stewart S, Murphy N, Walker A. et al. The current cost of angina pectoris to the National Health Service in the UK. Heart 2003;89:848–53
- Liu JLY, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart 2002;88:597–603
- Brown AID, Garber AM. A concise review of the cost-effectiveness of coronary heart disease prevention. Med Clin North Am 2000;84:279–97
- Buck D, Godfrey C, Killoran A, Tolley K. Reducing the burden of coronary heart disease: health promotion, its effectiveness and cost. Health Educ Res 1996;11:487–99
- Francis K. Physical activity in the prevention of cardiovascular disease. Phys Ther 1996;76:456–67
- Goldman L, Phillips KA, Coxson P, et al. The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost. J Am Coll Cardiol 2001;38:1012–17
- Lightwood J. The economics of smoking and cardiovascular disease. Prog Cardiovasc Dis 2003;46:39–78
- Salkeld G, Phongsavan P, Oldenburg B, et al. The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Policy (Amsterdam) 1997;41:105–19
- World Population Database. United Nations 2002. 15–11–2003. [Last accessed 7 Nov 2006]
- Moise P, Jacobzone S. OECD study of cross-national differences in the treatment, costs and outcomes of ischaemic heart disease. OECD Health Working Paper 2003;3
- Marques-Vidal P, Ruidavets JB, Cambou JP, Ferrières J. Incidence, recurrence, and case fatality rates for myocardial infarction in southwestern France, 1985 to 1993. Heart 2000;84: 171–5
- Working Party on Social Policy. Summary of results from ischaemic heart disease study. OECD Workshop 2002;3
- Maier W, Camici P, Windecker S, et al. The European Registry of Cardiac Catheter Interventions. Eur Heart J 1997;23:1903–7
- BCIS Audit Returns 2001. British Cardiovascular Intervention Society 2002. 11–11–2003. [Last accessed 7 Nov 2006]
- Department of Health. Prescription Cost Analysis 2002. London, 2002